Morgan Stanley

Stratasys opens enrollment is 3DHEART pediatric clinical study

Wednesday, March 8, 2017

Stratasys, a 3D printing and additive manufacturing solutions company, announced enrollment is now open for 3DHEART, an investigator initiated trial. 3DHEART, which stands for 3DHearts Enabling A Randomized Trial, is a randomized, single-blind clinical trial to study the use of patient-specific 3D printed models in pre-operative planning for pediatric heart surgery. Stratasys is providing in-kind support with printing of the models to be used in the trial.

[Read More]

Ariad appoints Alexander J. Denner to board of directors

Monday, February 24, 2014

Ariad Pharmaceuticals, an integrated global oncology company, has appointed Alexander J. Denner, Ph.D., to a two-year term on the company’s board of directors, effective immediately. With the addition of Denner, who is the chief investment officer and founding partner of Sarissa Capital Management LP, the board now comprises nine directors, eight of whom are independent. The company also will appoint another independent director to the board, who will be selected by the board and be subject to Denner’s concurrence.

[Read More]